Perrigo announced the launch of an AB rated generic version of Mycolog II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram).
Mycolog II Cream is indicated for the treatment of cutaneous candidiasis. Annual market sales for the generic versions of Mycolog II Cream for the 12 months ended September 2017 were approximately $81 million according to IMS Health.
"This launch exemplifies Perrigo's ongoing commitment to developing quality, high value alternatives in important treatment categories,” Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski said. “The Rx team continues to leverage our extended topicals strategy and development capabilities to deliver Quality Affordable Healthcare Products to customers, consumers and families around the world."